AstraZeneca Pharma gets DCGI nod to market asthma drug

Updated : December 21, 2020 11:57:21 IST

Drug firm AstraZeneca Pharma on Monday said it has received marketing authorisation from Drug Controller General of India for Benralizumab solution, indicated as an add-on maintenance treatment for severe asthma. AstraZeneca Pharma India Ltd has received import and market permission in Form CT-20 (marketing authorisation) from the Drugs Controller General of India for Benralizumab 30mg/ml solution for injection (Fasenra), the drug firm said in a regulatory filing.

Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

AstraZeneca Pharma said the receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt of related statutory approvals and licenses.

Shares of AstraZeneca Pharma India were 1.22 percent higher at Rs 4,936.05 apiece on BSE.

Published : December 21, 2020 11:57 AM IST

AstraZeneca Pharma gets DCGI nod to market asthma drug

You May Also Like

Indian hotel industry takes over Rs 1.30 lakh crore revenue hit in FY21, seeks govt support: FHRAI

Covishield, Covaxin generate half antibodies against B.1.617 COVID-19 variant compared to original strain: Report

Cairn Energy sues Air India to enforce $1.2 billion arbitration award

Trending on CNBC-TV18

recommended for you